Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06130046 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

Study acronym: DARE
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 1, 2025 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.
Trial Details
NCT Number NCT06130046
Lead Sponsor University of Rome Tor Vergata
Conditions
(from sponsor)		 Kidney Transplant; Complications, Liver Transplant; Complications
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov